Technetium-99m labelled antimicrobial peptides discriminate between bacterial infections and sterile inflammations

Smith JT. The mode of action of 4-quinolones and possible mechanisms of resistance. J Antimicrob Chemother 1986; 18 (Suppl D): 21–29. Wilson APR, Gruneberg RN. Ciprofloxacin -10 years of clinical experience. Oxford: Maxim Medical; 1997: 7–11. Brown EM, Reeves DS. Quinolones. In: O'Grady F, Lambert HP, Finch RG, Greenwood D, eds. Antibiotic and chemotherapy. New York: Churchill Livingstone; 1997: 419–432. Nuclear Imaging for Infection and Inflammation, A Coordinated Research Project E1.30.14 Technical document. Vienna: International Atomic Energy Agency; 2000: 1–152. Vinjamuri S, Hall AV, Solanki KK, et al. Comparison of 99mTcInfecton imaging with radiolabelled white-cell imaging in the evaluation of bacterial infection. Lancet 1996; 347: 233–235. Britton KE, Vinjamuri S, Hall AV, et al. Clinical evaluation of technetium-99m Infecton for the localization of bacterial infection. Eur J Nucl Med 1997; 24: 553–556. Hall AV, Solanki KK, Vinjamuri S, Britton KE, Das SS. Evaluation of the efficacy of 99mTc-Infecton, a novel agent for detecting sites of infection. J Clin Pathol 1998; 51: 215–219. Lehrer RI. Editorial response: questions and answers about defensins. Clin Infect Dis 1997; 25: 1141–1142. Welling MM, Nibbering PH, Paulusma-Annema A, et al. Imaging of experimental bacterial infections with a 99mtechnetium labeled antimicrobial human neutrophil peptide-1. J Nucl Med 1999; 40: 2073–2080.